Clinical Predictive Circulating Peptides in Rectal Cancer Patients Treated with Neoadjuvant Chemoradiotherapy

Sara Crotti, Maria Vittoria Enzo, Chiara Bedin, Salvatore Pucciarelli, Isacco Maretto, Paola Del Bianco, Pietro Traldi, Ennio Tasciotti, Mauro Ferrari, Flavio Rizzolio, Giuseppe Toffoli, Antonio Giordano, Donato Nitti, Marco Agostini

Research output: Contribution to journalArticle

Abstract

Preoperative chemoradiotherapy is worldwide accepted as a standard treatment for locally advanced rectal cancer. Current standard of treatment includes administration of ionizing radiation for 45-50.4Gy in 25-28 fractions associated with 5-fluorouracil administration during radiation therapy. Unfortunately, 40% of patients have a poor or absent response and novel predictive biomarkers are demanding. For the first time, we apply a novel peptidomic methodology and analysis in rectal cancer patients treated with preoperative chemoradiotherapy. Circulating peptides (Molecular Weight

Original languageEnglish
Pages (from-to)1822-1828
Number of pages7
JournalJournal of Cellular Physiology
Volume230
Issue number8
DOIs
Publication statusPublished - Aug 1 2015

    Fingerprint

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Cell Biology
  • Physiology
  • Medicine(all)

Cite this

Crotti, S., Enzo, M. V., Bedin, C., Pucciarelli, S., Maretto, I., Del Bianco, P., Traldi, P., Tasciotti, E., Ferrari, M., Rizzolio, F., Toffoli, G., Giordano, A., Nitti, D., & Agostini, M. (2015). Clinical Predictive Circulating Peptides in Rectal Cancer Patients Treated with Neoadjuvant Chemoradiotherapy. Journal of Cellular Physiology, 230(8), 1822-1828. https://doi.org/10.1002/jcp.24894